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The recently published Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult
Patients in the Intensive Care Unit differ from earlier guidelines in the following ways: literature searches were
performed in eight databases by a professional librarian; psychometric validation of assessment scales was
considered in their recommendation; discrepancies in recommendation votes by guideline panel members are
available in online supplements; and all recommendations were made exclusively on the basis of evidence available
until December of 2010. Pain recognition and management remains challenging in the critically ill. Patient
outcomes improve with routine pain assessment, use of co-analgesics and administration as well as dose
adjustment of opiates to patient needs. Thoracic epidurals help ease patients undergoing abdominal aortic surgery.
Little data exists to guide clinicians as to the type or dose of co-analgesics; no opiate choice is associated with
better patient outcomes. Lighter or no sedation is beneficial, and interruption is desirable in patients who require
deep sedation for specific pathologic states. Delirium screening is probably useful; no treatment modality can be
unequivocally recommended, and the benefit of prophylaxis is established only for early mobilization. The details of
these recommendations, as well as more recent publications that complement the guidelines, are provided in
this commentary.Review
Introduction
The Clinical Practice Guidelines for the Management of
Pain, Agitation, and Delirium in Adult Patients in the
Intensive Care Unit was recently published [1]. This
commentary summarizes the guidelines process, its ef-
forts to ensure transparency and scientific rigor as well
as describing some areas that remain controversial. How
these guidelines differ from earlier versions, knowledge
gaps, and which questions they do and do not answer
are described below.
How these guidelines differ from others
Four methodological characteristics differentiate these
guidelines from earlier versions. First, technical support
was provided by a research librarian, Charlie Kishman,
from the University of Cincinnati, who provided ongoing* Correspondence: skrobik@sympatico.ca
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reproduction in any medium, provided the origsearches from eight distinct databases. Expertise in com-
piling data from a maximum of high-yield sources, and
the thoroughness and methodology required to collate
search terms and compile the results, impacts the quality
guidelines or systematic reviews [2]. The convenience of
having all relevant triaged articles land in an e-mail
inbox (to be screened by team members from the pain
and analgesia, agitation and sedation, delirium, and re-
lated clinical outcomes teams) cannot be overstated. The
relevant articles were triaged in an online reference
RefWorks site accessible to all members, for more
manageable ongoing discussions and subsequent refe-
rencing. Second, all team members committed to focu-
sing on published evidence in critically ill adults. No
clinical experience-based opinion was incorporated in
these guidelines, nor was any recommendation made
where no evidence existed. Third, team member votes
on the various recommendations were made public for
readers to have access to the vote distribution. The
intent, in addition to transparency and rigor, was toer. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Skrobik and Chanques Annals of Intensive Care 2013, 3:9 Page 2 of 9
http://www.annalsofintensivecare.com/content/3/1/9underscore that even in the context of rigorous evidence
judgment plays a role in final attribution of scientific
value and of importance. The GRADE method of assess-
ment was chosen for ranking the evidence [3]. GRADE’s
value as a barometer of evidence has not been demon-
strated, nor has its reliability and agreement among
experts [4]. Publishing the votes allows the guidelines
reader to independently view the extent of concordance
among voters grading the evidence contained within
these guidelines. Fourth, the guidelines incorporate a
variety of bedside behavioral assessment tools used to
detect and evaluate pain, assess depth of sedation and
degree of agitation, and detect delirium. No comparative
assessments of the psychometric properties (i.e., scale re-
liability and validity) and feasibility of these tools for use
in intensive care unit (ICU) patients are published. The
assessment of the psychometric properties of applying
pain, sedation and delirium scales to ICU patients [5]
was undertaken, another first for this type of guideline.
Behavioral pain scales used in adult ICU patients were
analyzed and compared adapting a previously published
process [6]. Psychometric scoring systems were not avai-
lable to evaluate and compare the psychometric proper-
ties of sedation and delirium scales, which have different
validation strategies from those used for pain scales. The
task force members undertook the development of simi-
lar psychometric scoring systems to assess and compare
sedation and delirium scales, calling upon the expertise
of psychometric experts and using accepted theoretical
principles of health scale development and psychometric
testing [5].
Conflict of interest declarations were left up to the in-
dividual authors; each author chose whether associations
with different pharmaceutical industry partners consti-
tuted conflict. Experts with no conflicts are hard to find;
some argued that being conflicted does not affect your
judgment as to the quality of evidence [7]. Consensus
among experts is subject to halo effects because of the
group discussion process, where influence is challenging
to differentiate from learning from each other and exchan-
ging information. The strength of recommendations were
ranked as strong (1) or weak (2), and either in favor of an
intervention (+) or against (−) an intervention. For all
strong recommendations, the phrase “We recommend. . .”
was used. A weak recommendation indicated a less clear
trade-off or weaker evidence; the phrase “We suggest. . .”
was then used. In the absence of sufficient evidence, or
when group consensus could not be achieved, no recom-
mendation (0) was made.
Pain assessment and analgesia
The current guidelines address several new dimensions
of pain assessment and management described below.
Several other areas remain unexplored, largely becauseof a dearth in publications; these also are summarized
below.
Pain in ICU patients
Incidence, consequences and outcomes
The current guidelines emphasize that pain is frequent
in ICU patients [8], with an incidence of up to 50% in
medical and surgical patients at rest [9], and increasing
up to 80% during common care procedures. Since tra-
cheal suctioning and drain removal as well as turning
the patients for nursing-care procedures is reported as
the most painful routine care procedures [10], routine
preemptive analgesics in these circumstances are re-
commended. Pain in medical patients, which often is
attributable to immobilization, can be addressed with
early physiotherapy [11] and lighter sedation regimens
as the current sedation and delirium portions of the
guidelines suggest [1] (“We recommend performing early
mobilization of adult ICU patients whenever feasible to
reduce the incidence and duration of delirium (+1B);
and We recommend either daily sedation interruption or
a light target level of sedation be routinely used in mech-
anically ventilated adult ICU patients (+1B)”).
Long-term outcomes associated with pain or its
management
The association between pain in ICU patients and the
development of chronic pain syndrome in ICU survivors
is not addressed [12] as studies published after December
2010 were not included in the evidence review and voting
process. Posttraumatic stress disorder (PTSD) is attributed
to pain memories in some studies [13-15]. Although one
pediatric and one war-trauma study suggest more fre-
quent use of morphine might reduce the risk of sub-
sequent development of PTSD-related symptoms after
injury [16,17], these findings have not been documented
in an adult critical care population.
As these guidelines point out, improved pain manage-
ment is clearly associated with better patient outcome
in the ICU [8,18,19]. At least three studies performed in
surgical, trauma, and medical ICUs report that a pro-
tocolized approach to assess and manage pain, agitation,
and delirium [20] is associated with a reduced dura-
tion of mechanical ventilation, ICU acquired infections,
length of stay and costs in ICU, and hospital as well as
30-day mortality [8,18-21]; accordingly, the guidelines
recommend protocolized pain screening and assessing
analgesic needs first to palliate the current under-
recognition and treatment of pain [22].
Pain assessment
In patients able to communicate, self-report is without a
doubt the most reliable method to assess pain [23]. The
most commonly used are the Visual Analogue Scale
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Numeric Rating Scale (NRS). A prospective comparison
of five popular self-report pain scales in terms of their
feasibility, validity, and performance suggests that NRS-V
is the most feasible and the pain scale preferred by pa-
tients [24]. Self-report pain tools were not rated by, but
the NRS-V was considered preferable for pain detection
in ICU patients. The thresholds for pain that usually trig-
ger therapeutic interventions are defined by a V-NRS
score greater than 3 points (scale range 0–10).
Since the review of pain measurement instruments
available for ICU patients by Hamill-Ruth and Marohn
[23] more than a decade ago highlighting the absence of
validated instruments for critically ill patients, several
new behavioral pain instruments have been described in
the literature and were reviewed for guideline purposes
[19,25-29]. Recent reviews [6,30] of these instruments
concluded that only the Behavioral Pain Scale (BPS) [19]
and the Critical Care Pain Observation Tool (CPOT)
[27] provide acceptable levels of validity and reliability;
these two behavioral scales now constitute the two re-
commended nonverbal pain screening techniques. The
BPS was initially elaborated to assess pain in nonverbal,
mechanically ventilated patients without severe head
injury [19,31,32] with three behavioral domains: facial
expression, upper limb movements, and compliance with
ventilation. The CPOT has a fourth domain (muscle
tension), which may be the most psychometrically valid
of all in selected patients [27], such as the neurologically
critically ill [33]. The BPS requires that ventilator asyn-
chrony be observed while the patient undergoes a pain-
ful stimulus before attributing the asynchrony to pain,
whereas the CPOT does not stipulate this requirement;
this limitation is not addressed in the current guidelines.
In addition, the CPOT has a vocalization domain to
allow pain assessment in nonintubated patients, but this
dimension’s psychometric properties have yet to be vali-
dated. More recently, a vocalization domain was added
to the BPS, demonstrating good psychometric properties
in ICU nonintubated patients [34]. Vital signs, such as
heart rate and blood pressure, are unreliable as pain as-
sessment surrogates in ICU patients compared with be-
havioral parameters [33-35]; the guidelines make this
point and emphasize the need for systematic and ri-
gorous pain assessment, particularly because ICU pa-
tients’ pain is consistently underrated by ICU caregivers
[36-38]. Behavioral pain tools should not be used in
communicative patients, because correlation coefficients
between BPS and self-reported pain scales are low [24].
Treatment
No analgesic medication is associated with improved pa-
tient outcome. Opioids were used in up to 90% of mech-
anically ventilated patients in a multicenter patient-basedstudy [39]. Accordingly, the guidelines “. . .recommend
that IV opioids should be considered as the first-line drug
class of choice to treat nonneuropathic pain in critically ill
patients (+1C).” How these opioids should be adminis-
tered is not addressed. The continuous use of opioids may
lead to drug and metabolite accumulation [40,41]. Intra-
venous perfusions are not mandatory; indeed, escalation
of bolus opioids with or without continuous opiate infu-
sion in ICU patients is feasible patients and associated
with improved outcome [8,18,20].
A study performed in ICU patients (70% of whom
were surgical) used a gradual escalation of analgesics
from nonopioid drugs to incrementally powerful opioids
[8]. In that study, tramadol use increased significantly,
whereas incidence of pain and duration of mechanical
ventilation decreased. Co-analgesia with nonopioids was
introduced two decades ago [42] and is widely practiced
for treating postoperative pain. In keeping with this
rationale and despite the dearth of studies addressing
co-analgesia effectiveness in critically ill patients, the
guidelines suggest “. . .that nonopioid analgesics be con-
sidered to decrease the quantity of opioids administered
(or to eliminate the need for IV opioids altogether) and to
decrease opioid-related side effects (+2C).” In patients
with end-stage liver disease, reduced dosing acetamino-
phen appears to be safe [43]. Nefopam, a centrally acting
nonopioid agent proposed as an adjuvant to opioid anal-
gesics, relieves moderate to severe pain in ICU patients
without respiratory or neurological effects [44]. This de-
scription was published in 2011, after the final ratings
and votes had been established for the publications
being reviewed. Finally, gabapentin is effective for pain
treatment opioid consumption reduction in ICU pa-
tients with Guillain-Barré syndrome [45]. This, and a
similar study by the same group [46], led to the re-
commendation “. . .that either enterally administered
gabapentin or carbamazepine, in addition to intrave-
nous IV opioids, should be considered for treatment of
neuropathic pain (+1A).”
Regional analgesia (continuous epidural or peripheral
nerve blocks) is known to improve the efficacy of trad-
itional analgesic interventions and to decrease pulmon-
ary complications in many postoperative patients [47].
Its integration into practice is variable over time and by
European geographic region [48-50]. A multicenter stu-
dy that included 1,416 continuous peripheral nerve
blocks identified ICU stay as an independent factor as-
sociated with complications, such as hypoesthesia/pa-
resthesia, local inflammation, and infection [50]. Use
of regional analgesia in ICU patients deserves further
evaluation in regards of its benefits, feasibility, side ef-
fects, and contraindications. Accordingly, the guidelines
recommendations are cautious and limit their recom-
mendation for regional anesthesia in the only population
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beneficial [51,52]. “We recommend that thoracic epidural
anesthesia/analgesia should be considered for postopera-
tive analgesia in patients undergoing abdominal aortic
surgery (+1B). We provide no recommendation for the
use of a lumbar epidural over parenteral opioids for post-
operative analgesia in patients undergoing abdominal
aortic aneurysm surgery, due to a lack of benefit when
these routes of administration are compared in this pa-
tient population (0,A). We provide no recommendation
for the use of thoracic epidural analgesia in patients
undergoing either intrathoracic or nonvascular abdom-
inal surgical procedures, because of insufficient and
conflicting evidence for this mode of analgesic delivery in
these patients (0, B). We suggest that thoracic epidural
analgesia may be considered for patients with traumatic
rib fractures (+2B). We provide no recommendation for
neuraxial/regional analgesia over systemic analgesia in
medical ICU patients, due to lack of evidence in this pa-
tient population (0, No Evidence)”.Critical care analgesia research perspectives: beyond the
guidelines
The biology underpinning pain syndromes remains un-
derexplored, particularly in medical ICU patients. Hy-
peralgesia associated with sepsis could contribute to a
possible “diffuse ICU pain syndrome.” Indeed, myalgia
and arthralgia are common clinical features associated
with sepsis and fever [53], partly because of inflamma-
tion and muscle hypercatabolism induced by thermogene-
sis [54]. Inflammatory cytokines and sympathetic amines
are associated with a nociceptive state associated with in-
flammation and sepsis [55,56].
Barriers associated with pain not being evaluated by
health caregivers should be better elucidated [55,56].
In patients unable to communicate, electrophysiological
measurements could allow for objective measurement of
pain. The measurement of pupil size (pupillometry) ap-
pears to be more sensitive than behavioral parameters in
a population of ICU patients undergoing nociceptive
procedures [57]; whether pupillometry is useful com-
pared with behavioral parameters during suctioning is
less clear [58]. Which pain threshold should trigger anal-
gesic administration is not well established. Randomized,
controlled studies are still needed to demonstrate the
association between pain assessment, analgesia, and
short- and long-term outcomes (PTSD, chronic pain
syndromes, and quality of life). Which pharmacologic
interventions are useful, particularly with regards to
co-analgesia, is uncertain. Surprisingly, there is a dearth
of information on the use of acetaminophen/paraceta-
mol or of anti-inflammatory agents in the ICU popula-
tion [59,60].Nonpharmacological adjuncts or substitutes to phar-
macological intervention also are of interest. Music the-
rapy and music are beneficial for critically ill patients.
This unaddressed area in the literature is acknowledged
in the current guidelines, which state: “Complimentary,
nonpharmacologic interventions for pain management,
such as music therapy and relaxation techniques, can
be considered as complementary therapies in pain ma-
nagement; they may be opioid-sparing and analgesia-
enhancing choices, and they are low cost, easy to provide,
and safe.” Although a multimodal approach to pain ma-
nagement in ICU patients has been recommended, few
studies have demonstrated the effectiveness of nonphar-
macologic interventions [20,61,62].
Sedation assessment and management
The current guidelines support the minimization of sed-
ation so that patients are responsive and able to commu-
nicate. In clinical contexts where this is not possible or
not desirable, daily interruption of sedation is encou-
raged. The recommendations take into account subse-
quently published data suggesting that interruption
confers no additional advantage to sedation minimi-
zation [63]; although these publications were not avail-
able to the guidelines committee, the preliminary data
were known and thought to be harmonious with the
statements put forward earlier. These suggestions are
novel compared with earlier guidelines, where the em-
phasis was on patient comfort but not necessarily of the
harm inherent to sedatives. At the heart of earlier delib-
erations stood the conviction on the part of many care-
givers that sedation mitigates how traumatic the patient
perceives the ICU experience to be. This notion is slowly
being contradicted by data from follow-up studies [64].
There is emerging understanding that excessive sedation,
even when limited to 48 hours [65], is common and is
associated with increased morbidity, mortality, and ex-
penditure [65,66]. Daily interruption of sedative infu-
sions, titration of sedative dose and opiates to symptoms
[8,20,67], and minimization of drug administration is as-
sociated with patient benefit, reduced costs [21], and
does not lead to accidental device removal or psycho-
logical stress [68]. The contrast to earlier guidelines is
the explicit statement that harm is likely with iatrogenic
coma; this point is made both in the sedation and deli-
rium sections.
Despite review of the literature for the 10 years pre-
ceding the inception of the guidelines and during the
7 years spent in its creation, no clear recommendation
could be put forward with regard to preferred sedation
agent. Few topics generated as much controversy and
discussion as the use or avoidance of benzodiazepines,
leading to heated debates during panel discussions and
to perspective-defining publications [69,70]. The answer
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tion, instead of sedation with benzodiazepines, be used in
mechanically ventilated adult ICU patients? (actionable)
was reworded numerous times.
In parallel with the literature on continuously ad-
ministered analgesic agents, few data report the phar-
macokinetic properties of continuously administered
benzodiazepines, propofol, and dexmedetomidine [71].
Any comparison of these agents should take into ac-
count the variability in half-life, terminal half-life, and
changes associated with co-administration of compe-
titive metabolic pathway agents, inflammatory status,
and renal and hepatic dysfunction [70]. Dexmedetomidine
was not labeled as preferable sedative agent except in deli-
rious patients’ continuous sedation, where it is preferable
to benzodiazepines. Cost also is a concern; benzodiaze-
pines remain the least expensive molecule, albeit one sub-
ject to pharmacokinetic properties specific to the critically
ill; the benefits of choosing any agent have to be consid-
ered in the light of the current context of health care cost
containment policies in America and Europe [72,73].
Delirium
Routine delirium assessment in all critically ill patients is
recommended, in keeping with ICU guidelines published
by others [74]. This shift in attributing importance to
ICU delirium screening is integrated into regional or
national accreditation requirements; for instance, ICU
delirium screening is now mandated across Canada. Psy-
chometric properties were assessed based on scale reli-
ability and validity, and feasibility in critically ill adults.
Scales were then rated on 1) item selection and con-
tent validation, 2) reliability, 3) validity, 4) feasibility, and
5) relevance or impact of implementation on patient
outcomes, with regard to the scoring of delirium. The
Intensive Care Delirium Screening Checklist (ICDSC)
and the Confusion Assessment Method-ICU (CAM-ICU)
were considered best. The presence of the original crea-
tors of these scales on the guidelines panel was not con-
sidered a conflict of interest; the psychometric validation
was performed independently from their input. Two ca-
veats should be considered: 1) the psychometric validation
process, although performed by experts, was not peer-
reviewed (by its publication or in any other form), in con-
trast to all other material considered for these guidelines;
2) despite application of rigorous psychometric validation
principles, the fact that these two psychometrically valid
scores detect ranges of delirium from 10% to >80% in
similar populations was not accounted for.
The importance of delirium screening is emphasized
to reassure patients and provide prognostic indicators.
The recommendation that screening be performed with
a tool rather than with clinical assessments by intensive
care physicians was based on studies where deliriumscreening was introduced de novo [18] and by the strong
opinions held by guidelines writers. A recent (unpub-
lished until March 2013) study suggests, however, that
clinical assessments by critical care physicians may iden-
tify delirium more rapidly and more accurately than
screening tool assessments [75], a perhaps unsurprising
finding. Delirium prevention is highlighted for the first
time, with emphasis on early mobility as a safe and ef-
fective way of not only preventing delirium but provid-
ing patients with a more functional outcome at hospital
discharge. Risk factors for ICU delirium are inconsistent
across studies; those retained had to have been identified
in at least two studies: these were preexisting dementia;
history of hypertension; history of alcoholism; and ad-
mission a high severity of illness on admission. Some
publications associate continuously administered benzo-
diazepine and delirium in critically ill patients [76,77].
Because continuously sedating patients with midazo-
lam appears to be associated with a higher incidence of
delirium than sedating patients with dexmedetomidine
[78], and because this difference is not seen when mor-
phine is compared to dexmedetomidine [79], midazolam
has been presumed to be linked to delirium occurrence.
A more recently published study suggests midazolam
levels are in fact lower in patients who develop delirium
[80]. The Confusion Assessment Method (CAM-ICU)
screening tool was used to detect ICU delirium in stud-
ies that described less delirium with dexmedetomidine, a
molecule that is associated with greater wakefulness
than midazolam. Some authors have suggested that the
CAM-ICU scoring may be affected by sedation [81]; the
potential that the greater sedation seen and expected
with midazolam was a confounder for delirium remains
to be clarified before convincing conclusions can be
drawn. With regard to more recently established risk
factors for ICU delirium, the pre-deliric score [82] had
not been published at the time of guideline writing; its
risk stratification was not included in the guidelines
document, and the risk prediction is currently being va-
lidated in an international multicenter study.
Delirium prophylaxis was addressed for the first time
in these guidelines. To the question: “Should a non-
pharmacological delirium protocol in the ICU be used in
the ICU to reduce the incidence or duration of delirium?
(actionable),” the guidelines provide the following an-
swer: “We recommend that performing early mobili-
zation of adult ICU patients be performed whenever
feasible to reduce the incidence and duration of delirium
(+1B).” This recommendation is based on the first multi-
center, randomized, controlled trial of early mobility [11]
and a subsequent implementation study, where investi-
gators noted striking reductions in the incidence of de-
lirium in mobilized patients. These studies also indicate
that early and aggressive mobilization is unlikely to harm
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going studies aiming to prove the benefit of multi-
component prevention [83] are currently under way.
No recommendations were made with regard to phar-
macological delirium prevention. Six randomized studies
evaluating a pharmacologic intervention for ICU pa-
tients had been published at the time of review. Al-
though a reduction in delirium was observed in five of
the studies, important methodological differences and
limitations may have influenced some of the results
[84,85], whereas other studies were limited to very nar-
row patient population [86,87]. Although use of dexme-
detomidine as a sedative during elective cardiac surgery
was associated with less delirium than propofol or mi-
dazolam [85], a subsequent study that was nearly four
times larger found that use of dexmedetomidine resulted
in a similar incidence of delirium compared with
morphine-only sedation regimen [79]. In both of these
sedation studies, delirium incidence was measured using
the CAM–ICU; it remained unclear whether some of
the patients deemed to have delirium actually had deli-
rium or were simply sedated [88].
Given these data, no pharmacologic prophylaxis rec-
ommendation for delirium was made; a recent system-
atic review of delirium prophylaxis in the critically ill
concurs with the lack of evidence to support this prac-
tice [89]. However, the reduction in subsyndromal delir-
ium shown in one study was acknowledged as follows:
“One before/after study evaluated the impact of a multi-
disciplinary protocol for managing pain, agitation, and
delirium in ICU patients.” This study demonstrated a re-
duction in the incidence of subsyndromal delirium (but
not delirium), with improved pain control, and without
compromising sedation or anxiolysis, and a 15% reduc-
tion in their total ICU costs [20,21]. Subsyndromal delir-
ium in ICU patients is defined as patients who have <4
points on the ICDSC; patients with subsyndromal de-
lirium have worse clinical outcomes than those without
delirium [90].
After the guidelines had been written, the largest ICU
delirium prophylaxis study published to date described
that a low-dose, 12-hour infusion of haloperidol reduces
the incidence of delirium in surgical patients from 23%
to 15% (p = 0.03) [91]. As the average APACHE scores
were 9, the generalizability of these findings to the broad
ICU population is not clear. However, encouraging pre-
liminary single-center pre-post European pilot studies
[92] have shown reductions in delirium incidence and
duration in patients considered at high risk after pro-
phylactic low doses of haloperidol, and support mo-
ving forward with multicenter prophylaxis trials in
high-risk ICU populations. All successful prophylaxis
studies to date have included surgical patients exclusive-
ly. In a well-conducted, but underpowered, multicenter,randomized, controlled pilot of delirium prophylaxis in
medical ICU patients with antipsychotics (either haloperi-
dol or ziprasidone vs. placebo) did not show any benefit
with either haloperidol or ziprasidone compared with pla-
cebo [93].
The guidelines are clear as to the paucity of evidence
supporting any pharmacologic treatment for delirium.
With the possible exception of a benefit shown in a
small (n = 36) study randomizing patients on as-needed
haloperidol to quetiapine [94], where patients with que-
tiapine had shorter delirium duration, no drug has been
shown to improve delirium outcome once it as occurred.
Accordingly, the treatment section of the guidelines is
clear: “Question: Does treatment with haloperidol reduce
the duration of delirium in adult ICU patients? (descrip-
tive) Answer: There is no published evidence that treat-
ment with haloperidol reduces the duration of delirium
in adult ICU patients (No Evidence), and Question: Does
treatment with atypical antipsychotics reduce the du-
ration of delirium in adult ICU patients? (descriptive)
Answer: Atypical antipsychotics may reduce the duration
of delirium in adult ICU patients (C).” A recent review
of delirium treatment in ICU patients [95] concedes that
there is limited evidence on the safety and effectiveness
of antipsychotics in ICU delirium.
Rivastigmine use in the critically ill is specifically
discouraged in the guidelines: “We do not recommend
administering rivastigmine to reduce the duration of de-
lirium in ICU patients (−1B).” Although tested in only
one study, when rivastigmine was compared with pla-
cebo in critically ill patients the investigation was halted
because of perceived futility and potential harm by the
DSMB (Data Safety Monitoring Board) [96]; rivastigmine-
treated patients were found to have more severe and
longer delirium, with a trend toward a higher morta-
lity rate. Delirium in association to alcohol withdrawal
was not covered in these guidelines because of space
considerations; this topic is reviewed in a separate publi-
cation [95].
Conclusions
The current guidelines update the critical care clinician
on the importance of pain and delirium assessments and
the need to minimize or interrupt sedation. The me-
thodological rigor with which the evidence was triaged
improves the clarity and scientific basis of the recom-
mendations; the guidelines also better identify gaps in
current evidence. We hope that the current update on
guideline content and process will incite critical care in-
vestigators to build on established work to address pain,
sedation, and delirium issues in order to improve care
and outcomes for the critically ill and to reduce the sig-
nificant burden of critical illness on patients, their families,
and society.
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